

## Abstracts in International Conferences 2024

---

1. Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents. Jonathan R Strosberg, Anna Koumarianou, Rachel Riechelmann, Jorge Hernando, Sara Cingarlini, Joakim Crona, Taymeh E Al-Toubah, Leonidas Apostolidis, Emily K Bergsland, Thorvardur Ragnar Halfdanarson, Jerome Cros, Louis De Mestier DU Bourg. *Journal of Clinical Oncology American Society of Clinical Oncology. ASCO GI meeting 2025.*
2. 94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study. D Ziogas, H Linardou, A Charpidou, A Koumarianou, G Mountzios, P Kosmidis, C Christodoulou, D Mavroudis, AN Christopoulou, I Korantzis, S Baka, M Vaslamatzis, I Athanasiadis, A Koutras, D Mauri, A Kotsakis, A Visvikis, F Spanoudi, T Tschritzis, K Syrigos. *Immuno-Oncology and Technology, Volume 24, 100837.*
3. Georgakopoulos, A., Tsoli, M., Koumarianou, A., Papadopoulou, N., Panagaki, M., Kaltsas, G., & Chatziioannou, S. (2024, September). Significant Improvement of Quality of Life after first dose of Peptide Receptor Radionuclide Therapy (PRRT) in a Malignant Refractory Insulinoma: a Case Report Study. In *European Journal Of Nuclear Medicine And Molecular Imaging (Vol. 51, Pp. S875-S875)*. One New York Plaza, Suite 4600, New York, Ny, United States: Springer.
4. 1858P Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMaT and ACT4CAT studies. NG Tsoukalas, AN Christopoulou, E Timotheadou, A Koumarianou, A Ardavanis, I Athanasiadis, M Demiri, A Bokas, GF Samelis, S Peroukidis, G Papatsimpas, C Andreadis, C Kalofonos, A Psyrri, N Kapodistrias, P Papakostas, E Samantas, G Aravantinos, P Papakotoulas, I Boukovinas. *Annals of Oncology, Volume 35, S1094*
5. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Vanesa Gregorc, Maria González-Cao, Stefania Salvagni, Anna Koumarianou, Ignacio Gil-Bazo, Michele Maio, Santiago Viteri, Margarita Majem, Vanesa Gutiérrez, Reyes Bernabe Caro, Miguel F Sanmamed, Huaqiang Zhu, Haige Shen, Yu Wang, Rafael Rosell. Poster and Oral Presentation at ASCO 2024. *JCO 42, LBA8511-LBA8511(2024)*. DOI:10.1200/JCO.2024.42.17\_suppl.LBA8511
6. 115P Exploratory analysis of angioregulatory microRNAs 27a, 27b, 107, and 622 in the progression of colorectal cancer. Koumarianou A, Damalas A, Ntavatzikos A, Kampoli K, Patapis P, Rogdakakis A, Meimaris G, Foukas P, Arkadopoulos N. *Annals of Oncology, Volume 35, S54*
7. 33P Final Analysis of the Greek cohort of the AGENT Phase III study Arfolitixorin in Metastatic Colorectal Cancer. Koumarianou A, Bournakis E, Kotsakis A, Ntavatzikos A, Kampoli K, Kentepozidis N, Skintemo L, Tell R, Papadimitriou Ch. *ESMO Gastrointestinal Congress. Munich, Germany, June 26-29, 2024. Ann Oncol, 2024; Volume 35, S17*
8. 87P Real-World Evidence of FTD/TPI and Bevacizumab Combination Therapy in Metastatic Colorectal Cancer: Survival and Clinicopathological Insights. Koumarianou A, Ntavatzikos A, Symeonidis D, Vallilas Ch, Giannakakou M, Papaxoinis G, Xynogalos S, Boukovinas I, Demiri S, Kampoli K, Oikonomopoulos G, Samantas E, Res E, Androulakis N, Vourli G, Souglakos I, Karamouzis M. *ESMO Gastrointestinal Congress. Munich, Germany, June 26-29, 2024. Annals of Oncology, Volume 35, S42 – S43*
9. Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer. Georgios Pappas, Nikolaos Tsoukalas, Anastasios L Boutis, Emmanouil S Saloustros, Ioanna Gazouli, Stefania Gkoura, Roubini Zakopoulou, Chrysovalantis Aidarinis, Ioannis Boukovinas, Anna Koumarianou, Stefania Kokkali, Georgios Gkoumas, Panagiotis J Vlachostergios, Avraam Assi, Athanasios Karampeazis, Adamantia Nikolaidi, Elena Fountzilas, Natalia Chatzifoti, Zacharenia Saridaki. Abstract ASCO 2024. *JCO 42, e23139-e23139(2024)*. DOI:10.1200/JCO.2024.42.16\_suppl.e23139.
10. 142TiP SARC-Digital: An observational, randomized, prospective study of the impact of digital health interventions on symptom and side-effect management in patients with metastatic sarcoma. S Kokkali-Zervos, J Durán Moreno, A Kyriazoglou, V Georgoulas, I Athanasiadis, A Koumarianou, NG Tsoukalas, V Ramfidis, A Stergioula, PA Kosmidis, DA Valoukas, D Tzanninis, G Varvaris, PT Baxevanos, T Kosmidis, V Schoina, I Boukovinas. *ESMO Sarcoma and Rare Cancers Congress 2024, Lugano, Switzerland, 14-16 March, 2024. [https://www.esmoopen.com/article/S2059-7029\(24\)00335-1/fulltext](https://www.esmoopen.com/article/S2059-7029(24)00335-1/fulltext). Ann Oncol. 2024; 9 – (S2), p. 32 # 142TiP 2024*
11. 90P Real-world data on immunotherapy in patients with soft tissue sarcoma: A study from the Hellenic Group of Sarcoma and Rare Cancers. S Kokkali-Zervos, A Kyriazoglou, A Koumarianou, E Vorrias, N Asimakopoulou, A Boulouta, E Georgaki, AS Papadaki, A Stergioula, I Boukovinas. Ανακοινώθηκε στο ESMO Sarcoma and Rare Cancers Congress 2024. Lugano, Switzerland, 14-16 March, 2024. *Annals of Oncol. 2024; 9 – (S2), p. 102479*. DOI:<https://doi.org/10.1016/j.esmoop.2024.102479>. [https://www.esmoopen.com/article/S2059-7029\(24\)00247-3/fulltext](https://www.esmoopen.com/article/S2059-7029(24)00247-3/fulltext).
12. Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group. E Fountzilas, T Lalla, G Karakatsoulis, K Papazisis, K Exarchos, A Koumarianou, A Nikolaidi, I Binas, D Mauri, S Karageorgopoulou, E Razis, A Christopoulou, A Boutis, G Douganiotis, F Zagouri, S Stamatopoulou, N Spathas, D Tryfonopoulos, A Psyrri, A Koutras. 14th European Breast Cancer Conference (EBCC), Milan, Italy, 20-22 March, 2024. *Eur J Cancer. 2024 Mar; 200 (Suppl. 1), p. 113954*. DOI:<https://doi.org/10.1016/j.ejca.2024.113954>. [https://www.ejancer.com/article/S0959-8049\(24\)00179-5/abstract](https://www.ejancer.com/article/S0959-8049(24)00179-5/abstract)